And of course without getting our hopes up too much we must be getting close to announcing the end of PH2 meeting with the FDA for Pitt-Hopkins Syndrome,
This should be due in February 2025 roughly. That the begs the question if NEU got breakthrough for Phelan-McDermid Syndrome where does that leave Pity-Hopkins.
It’s hard to imagine one indication being approved for use and the second group waiting for 2-3 years for their treatment.
One things for sure if we get Breakthrough Designation the auction will really start hotting up. Because a Breakthrough Designation will draw a lot of attention to NEU.
And of course without getting our hopes up too much we must be...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 3278 | 1 |
View Market Depth
| Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |